Loss of expression of the type III transforming growth factor-b receptor (TbRIII or betaglycan), a transforming growth factor-b (TGF-b) superfamily co-receptor, is common in human breast cancers. TbRIII suppresses cancer progression in vivo by reducing cancer cell migration and invasion by largely unknown mechanisms. Here, we demonstrate that the cytoplasmic domain of TbRIII is essential for TbRIII-mediated downregulation of migration and invasion in vitro and TbRIII-mediated inhibition of breast cancer progression in vivo. Functionally, the cytoplasmic domain of TbRIII is required to attenuate TGF-b signaling, whereas TbRIII-mediated attenuation of TGF-b signaling is required for TbRIII-mediated inhibition of migration and invasion. Mechanistically, both TbRIII-mediated inhibition of TGF-b signaling and TbRIII-mediated inhibition of invasion occur through the interaction of the cytoplasmic domain of TbRIII with the scaffolding protein GAIP-interacting protein C-terminus (GIPC). Taken together, these studies support a functional role for the TbRIII cytoplasmic domain interacting with GIPC to suppress breast cancer progression.
Introduction
Transforming growth factor-b (TGF-b) is a member of a superfamily of cytokines involved in regulating and mediating a variety of normal and pathological processes, including wound healing, fibrosis and cancer progression (1, 2) . TGF-b signaling is initiated by the binding of TGF-b ligand to cell surface receptors. TGF-b binds either to the type III transforming growth factor-b receptor (TbRIII), which in turn presents TGF-b to the dimeric type II transforming growth factor-b receptor (TbRII) or directly to TbRII. Ligand binding to TbRII leads to recruitment of the type I transforming growth factor-b receptor (TbRI). TbRII then activates TbRI in the cytoplasmic domain, activating TbRI kinase activity. Subsequently, TbRI phosphorylates a receptor Smad, either Smad2/3 or Smad1/5/8. The phosphorylated receptor Smads bind to Smad4, and the consequent complex accumulates in the nucleus and regulates transcription of TGF-b-responsive genes in a cell-and context-specific manner (3) .
In normal mammary epithelial cells, TGF-b functions in ductal and glandular development as an inhibitor of proliferation (4) . In mammary carcinogenesis, TGF-b initially acts as a tumor suppressor as supported by murine models in which overexpressing TGF-b suppresses tumor formation (5) and a chemically induced breast cancer mouse model in which overexpressing dominant-negative TbRII enhances tumor progression (6) . Throughout breast cancer development, however, cells become increasingly resistant to the antiproliferative effects of TGF-b, and TGF-b then functions as a tumor promoter. Indeed, dominant-negative TbRII decreased lung metastatic potential in oncogenic Neu mice, whereas targeted expression of activated TbRI in the mammary glands increased lung metastases (7) .
While mutations in the TGF-b pathway are rare in human breast cancer, changes in expression of specific pathway components can contribute to breast cancer progression. For example, loss of TbRII expression correlates with high tumor grade and tumor invasiveness in early cancer progression (8, 9) , whereas in later stages, increased TGF-b levels in breast cancer patients correlate with poor prognosis (10) . In addition, we have previously identified TbRIII as an important suppressor of breast cancer progression, with frequent loss of TbRIII expression during breast cancer progression and shorter time to recurrence in breast cancer patients with decreased TbRIII levels. Restoring TbRIII expression was sufficient to inhibit breast cancer cell migration and invasion in vitro and breast cancer invasion and metastasis in vivo (11) . Importantly, these effects on migration, invasion and tumor progression are not confined to breast cancer but have also been demonstrated in non-small cell lung, ovarian, pancreatic and prostate cancer models (12) (13) (14) (15) .
Mechanistically, TbRIII appears to function as a suppressor of cancer progression through several discrete mechanisms. We have demonstrated that cell surface TbRIII undergoes ectodomain shedding, releasing the soluble extracellular domain, which can sequester TGF-b ligand to inhibit TGF-b signaling and inhibit invasion in breast cancer models in vitro and lung metastasis in vivo (11) . TbRIII also inhibits cancer cell migration through interacting with the scaffolding protein b-arrestin2 to activate Cdc42 and reduce directional persistence of cancer cells (16) .
The cytoplasmic domain of TbRIII is a relatively short region with no known intrinsic kinase activity. However, it is important in modulating TbRIII expression and in mediating downstream signaling. TbRII phosphorylates TbRIII's cytoplasmic domain at Thr841, resulting in b-arrestin2 binding (17) . This interaction is important for TbRIII internalization and ultimately leads to downregulation of TGF-b signaling. In addition, the adapter protein GAIP-interacting protein C-terminus (GIPC) binds to the PDZ-binding domain located at the terminal three amino acids of TbRIII. Depending on cellular context, the interaction of GIPC with TbRIII can either upregulate or downregulate cell surface expression (18) . In terms of signaling, evidence suggests that the cytoplasmic domain is critical in mediating downstream Smad signaling of TGF-b2 (19) . In addition, modulation of p38 mitogen-activated protein kinase signaling by TbRIII has been shown to depend on an intact cytoplasmic domain, independent of Smad signaling (20, 21) . These findings suggest that the cytoplasmic tail is important in the regulation of the expression of TbRIII at the cell surface and plays a role in mediating both Smad-dependent and Smad-independent signaling. Accordingly, here we examine the contribution of the cytoplasmic domain of TbRIII in mediating the suppressor of cancer progression role of TbRIII in vitro and in vivo.
and boiled for 5 min. Lysates were separated using sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels, transferred onto polyvinylidene difluoride membranes, blocked in 5% milk in phosphate-buffered saline/Tween and incubated overnight at 4°C with gentle agitation.
Fibronectin migration and Matrigel invasion assays
Fibronectin (Calbiochem, Gibbstown, NJ) was coated on transwells (Costar, Lowell, MA) at a concentration of 50 lg/ml in serum-free Dulbecco's modified Eagle's medium (DMEM), whereas Matrigel transwells (BD Biosciences, San Jose, CA) were preincubated with serum-free DMEM for 2 h at 37°C. For migration assays, 50 000 cells were plated in 200 ll of serum-free DMEM in the upper chamber; for invasion assays, 200 000 cells were plated in 200 ll of serum-free DMEM and allowed to migrate for 24 h toward 600 ll of 10% fetal bovine serum in DMEM. Cells on the upper surface were scraped with a cotton swab and wells were stained with three-Step Stain Kit (Richard-Allan Scientific, Kalamazoo, MI). Filters were then mounted on microscope slides with Vectamount (Vector Laboratories, Burlingame, CA). Three random fields on each filter were counted. Cells were plated in duplicate, and each experiment was conducted at least three times. I-TGF-b binding and cross-linking as described previously (11) . A total of 25 000 cells were injected into the right axillary mammary fat pad of 6-weekold virgin female Balb/c mice, using 15 mice in each group. After 12 days, the resulting primary tumors were excised, weighed and measured with calipers (volume calculated by 0.52 Â length Â width 2 ). Bioluminescent imaging with intraperitoneal injections of 150 lg/g luciferin (Xenogen, Hopkinton, MA) was conducted with an IVIS camera (Xenogen) every 3 days for 24 days. Regions of interest were defined automatically, and luciferase units are expressed as photons/s/cm 2 /steradian. Background signal was defined by imaging a mouse without luciferin. Mice were killed at the end of the study, organs visually inspected, and samples of interest preserved for immunohistochemical analysis.
In vivo metastasis

Immunohistochemistry
Tissue samples were formalin fixed, paraffin embedded and cut onto microscope slides. Slides were then either stained for hematoxylin and eosin or prepared for immunohistochemical analysis. Staining for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (Roche Diagnostics, Indianapolis, IN) and proliferating cell nuclear antigen (Santa Cruz Biotechnology) was performed according to manufacturer's instructions. Phospho-Smad2 staining (Cell Signaling Technology) was performed following antigen retrieval by boiling in Tris-ethylenediaminetetraacetic acid (10 mM Tris, 1 mM ethylenediaminetetraacetic acid and 0.05% Tween, pH 9.0) for 5 min.
Statistical analysis
All data are presented as mean ± SEM. Two-tailed Student's t-test was performed. P-values of ,0.05 were considered significant.
Results
TbRIII's cytoplasmic domain has a role in TbRIII-mediated inhibition of breast cancer cell migration and invasion We have previously demonstrated a role for TbRIII in inhibiting breast cancer metastases in vivo and cancer cell migration and invasion in vitro (11) . The cytoplasmic domain of TbRIII has a critical role in regulating TbRIII cell surface expression and endocytosis through its interaction with GIPC (18) and b-arrestin2 (17) . The cytoplasmic domain is also important in mediating TbRIII-dependent downstream signaling to both Smad-dependent (3, 19, 23) and Smadindependent signaling pathways (20, 24, 25) . Accordingly, to further define the mechanism by which TbRIII suppresses breast cancer progression, we investigated the specific contribution of the cytoplasmic domain of TbRIII in the 4T1 syngeneic murine model of mammary carcinogenesis.
Full-length TbRIII (TbRIII), TbRIII lacking the cytoplasmic domain (TbRIII-cyto) or empty vector (Neo) was stably expressed in the 4T1 cell line ( Figure 1A ). While TbRIII inhibited migration by $50% (Figure 1B) , consistent with our prior results (11), TbRIII-cyto failed to inhibit the migration of 4T1 cells ( Figure 1B ). In addition, while TbRIII expression inhibited invasion by $40%, TbRIII-cyto expression failed to inhibit invasion ( Figure 1C ). Interestingly, TbRIII-cyto slightly enhanced the invasive potential of 4T1 cells in comparison with the negative control ( Figure 1C ), although these results were not significantly different. These results suggest an important role for the cytoplasmic domain of TbRIII in TbRIII-mediated inhibition of breast cancer cell migration and invasion.
TbRIII's cytoplasmic domain contributes to TbRIII-mediated inhibition of migration and invasion by inhibiting TGF-b signaling Given TbRIII's known role in regulating TGF-b signaling, the contribution of the cytoplasmic domain of TbRIII to TGF-b signaling was examined. 4T1 cells stably expressing TbRIII, TbRIII-cyto or empty vector were stimulated with TGF-b and analyzed for activation of pathways known to be downstream of TGF-b and TbRIII, including the Smad2 (3), p38 (20, 21) and nuclear factor-kappaB (24,25) pathways. While TbRIII expression decreased TGF-b-mediated Smad2 phosphorylation, TbRIII-cyto expression had no effect ( Figure 2A , supplementary Figure 5A is available at Carcinogenesis Online). In contrast, activation of the nuclear factor-kappaB signaling pathway, as assessed by phosphorylation of p65 or inhibitor of kappa B levels, or p38 signaling, as assessed by phosphorylation of p38, was not differentially regulated by TbRIII and TbRIII-cyto (Figure 2A ), suggesting a specific role for cytoplasmic domain of TbRIII in negatively regulating TGF-b signaling.
To investigate whether the effects of TbRIII in inhibiting breast cancer cell migration and invasion might be through TbRIII-mediated attenuation of TGF-b signaling, we directly assessed the effect of altering TGF-b signaling on breast cancer cell migration and invasion. Consistent with a role for inhibition of TGF-b signaling directly inhibiting TGF-b signaling with the ALK5 pharmacological inhibitor SB431542 inhibited the migration of Neo and TbRIII-cyto to the same extent as TbRIII ( Figure 2B ). If TbRIII inhibits migration and invasion by inhibiting TGF-b signaling, we hypothesized that activating TGF-b signaling downstream of TbRIII utilizing constitutively active TbRI (ALK5QD) might bypass this inhibition. Consistent with this hypothesis, while ALK5QD expression had minimal effect on the migration or invasion of 4T1-Neo and 4T1-TbRIII-cyto cells ( Figure 2C and D), ALK5QD expression significantly attenuated TbRIII-mediated inhibition of migration ( Figure 2C ) and invasion ( Figure 2D ). Taken together, these data support a role for TbRIIImediated inhibition of TGF-b signaling in TbRIII-mediated inhibition of migration and invasion.
The interaction of TbRIII with GIPC is required for TbRIII-mediated suppression of TGF-b signaling and invasion As TbRIII-mediated inhibition of TGF-b signaling appears to have a predominant role in TbRIII-mediated inhibition of migration and invasion, we further investigated the mechanism of TbRIII action. TbRIII undergoes ectodomain shedding to release the soluble extracellular domain, soluble TbRIII (sTbRIII), which can function to bind and sequester ligand and can also inhibit breast cancer invasion (11, 26) . We initially investigated whether TbRIII and TbRIII-cyto differed in their ability to produce sTbRIII. Examining the conditioned media from 4T1-TbRIII and 4T1-TbRIII-cyto revealed that both TbRIII and TbRIII-cyto were shed to a similar extent (supplementary Figure 1A is available at Carcinogenesis Online). As the sTbRIII produced by TbRIII and TbRIII-cyto might function to differentially inhibit breast cancer migration or invasion, we examined the ability of conditioned media from 4T1-TbRIII and 4T1-TbRIIIcyto cells to inhibit 4T1 cell migration. Consistent with our prior results (11), conditioned media from TbRIII and TbRIII-cyto both inhibited 4T1 cell migration to a similar extent (supplementary Figure 1B is available at Carcinogenesis Online), further supporting that differential shedding was not responsible for differences in TbRIII-mediated inhibition of TGF-b signaling, migration and invasion between TbRIII and TbRIII-cyto.
We next investigated the contribution of specific previously defined TbRIII cytoplasmic domain functions, namely the interactions with scaffolding proteins GIPC and b-arrestin2. TbRIII mutants unable to bind b-arrestin2 (TbRIII-T841A) or GIPC (TbRIII-del, lacking three C-terminal amino acids) were expressed in 4T1 cells alongside with TbRIII and TbRIII-cyto (supplementary Figure 5B is available at Carcinogenesis Online), suggesting a specific role for this region of the cytoplasmic domain of TbRIII in inhibiting TGF-b signaling. To investigate the contribution of interactions with GIPC and b-arrestin2 on breast cancer invasion, we expressed TbRIII, TbRIII-cyto, TbRIII-T841A or TbRIII-del in 4T1 cells. Again, TbRIII inhibited invasion, whereas TbRIII-cyto did not ( Figure 3B ). Consistent with the TGF-b signaling data, TbRIII-T841A also inhibited invasion ( Figure 3B ), whereas TbRIII-del was completely unable to inhibit invasion ( Figure 3B ). The tight correlation between the ability of TbRIII mutants to inhibit TGF-b signaling ( Figure 3A , supplementary Figure 5B is available at Carcinogenesis Online) and inhibit breast cancer invasion ( Figure 3B ) supports a functional relationship between these effects. This functional relationship is further supported by the ability of pharmacological inhibition of ALK5 to inhibit invasion in the context of TbRIII-del expression ( Figure 3C ).
While deletion of the C-terminal three amino acids in TbRIII-del is known to abrogate the interaction of TbRIII with GIPC (18), this region could also mediate other TbRIII functions. To investigate the specific function of GIPC, we utilized short hairpin RNA-mediated silencing of GIPC expression, which efficiently decreased GIPC expression ( Figure 3D ). Consistent with a role for GIPC in TbRIIImediated inhibition of TGF-b signaling and breast cancer invasion, short hairpin RNA-mediated silencing of GIPC expression attenuated both TbRIII-mediated inhibition of TGF-b signaling ( Figure 3D , supplementary Figure 5C is available at Carcinogenesis Online) and TbRIII-mediated inhibition of invasion ( Figure 3E ). Taken together, these data support a model in which TbRIII through interacting with GIPC inhibits TGF-b signaling to inhibit breast cancer invasion.
The cytoplasmic domain of TbRIII has a role in TbRIII-mediated suppression of breast cancer progression Having established that the cytoplasmic domain of TbRIII has an important role in TbRIII-mediated inhibition of migration and invasion, coupled with our previous findings that TbRIII suppresses breast cancer metastases in vivo, we examined the role of the cytoplasmic domain of TbRIII in TbRIII-mediated suppression of breast cancer progression in vivo in the 4T1 syngeneic murine model of breast cancer. The 4T1 cells were stably cotransfected with a constitutively active luciferase reporter, which allowed the non-invasive in vivo tracking of cells during tumor development, along with either Neo, TbRIII or TbRIII-cyto. After cells were injected, primary tumors were allowed to develop for 12 days, after which they were surgically excised and assessed. After excision of the primary tumor, the Type III TGF-b receptor cytoplasmic domain in breast cancer formation of metastases was followed by bioluminescent imaging every 3 days over a period of 24 days. Consistent with our previous studies (11), there were no significant differences in primary tumor growth among the 4T1-Neo, 4T1-TbRIII or 4T1-TbRIII-cyto groups, as measured by both primary tumor mass and volume (supplementary Figure 3 is available at Carcinogenesis Online). However, consistent with our previous studies (11), mice with the 4T1-TbRIII cells had a delay tumor metastasis onset and decreased metastatic tumor burden as compared with mice injected with the control 4T1-Neo cells ( Figure 4A and D) . In contrast to the results with mice with the 4T1-TbRIII cells, mice with the 4T1-TbRIII-cyto cells had no delay in onset of tumor metastases and no decrease in metastatic tumor burden as compared with mice with the control 4T1-Neo cells ( Figure 4A and D) . Upon necropsy, the 4T1-Neo, 4T1-TbRIII and 4T1-TbRIII-cyto mice were examined for gross metastatic lesions. Consistent with bioluminescent imaging, significantly more lesions were found in the mice with 4T1-Neo cells and 4T1-TbRIII-cyto as compared with mice with 4T1-TbRIII cells ( Figure 4B and C). Further histological examination of the primary tumors demonstrated local invasiveness of the primary tumor into the stroma in the 4T1-Neo ( Figure 5A ) and 4T1-TbRIII-cyto ( Figure 5C ) tumors, whereas the 4T1-TbRIII tumors instead displayed a well-demarcated border with the surrounding stroma ( Figure 5B ). Furthermore, lung metastases from 4T1-Neo ( Figure 5D ) and 4T1-TbRIII-cyto ( Figure 5F ) tumors revealed invasion into the lung parenchyma, whereas lung metastases from 4T1-TbRIII tumors ( Figure 5E ) were smaller and well circumscribed. In addition, while 4T1-Neo and 4T1-TbRIII-cyto tumors both metastasized to the liver ( Figure 5G and I) , and a 4T1-TbRIII-cyto tumor metastasized to the kidney ( Figure 5J) , none of the 4T1-TbRIII tumors metastasized to these sites ( Figure 5H ). These studies support a specific suppressor effect of TbRIII on breast cancer invasiveness and metastasis mediated through its cytoplasmic domain.
To investigate the mechanism of the cytoplasmic domain of TbRIII on decreasing metastasis in vivo, we performed immunohistochemistry for proliferating cell nuclear antigen as a marker of proliferation in the primary tumor and lung metastases. There were no significant differences in proliferating cell nuclear antigen staining between 4T1-Neo, 4T1-TbRIII and 4T1-TbRIII-cyto tumors in either the primary or metastatic lesions (supplementary Figure 4A and B is available at Carcinogenesis Online). We also performed terminal 
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deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling staining as a marker of apoptosis in the primary tumor and lung metastases. Similarly, there were no significant differences observed between 4T1-Neo, 4T1-TbRIII and 4T1-TbRIII-cyto tumors for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling staining (supplementary Figure 4C and D is available at Carcinogenesis Online). These results suggested that differences in proliferation or apoptosis do not account for the differences in invasion and metastases among 4T1-Neo, 4T1-TbRIII and 4T1-TbRIII-cyto tumors.
As we had observed differences in TGF-b signaling between 4T1-Neo, 4T1-TbRIII and 4T1-TbRIII-cyto that potentially accounted for differences in cell migration and invasion in vitro, we explored whether differences in TGF-b signaling could account for differences in cancer progression in vivo. Tissues from 4T1-Neo, 4T1-TbRIII and 4T1-TbRIII-cyto tumors and their lung metastases were analyzed for phospho-Smad2 staining. Although there was no difference in phospho-Smad2 staining in the 4T1-Neo, 4T1-TbRIII and 4T1-TbRIIIcyto primary tumors ( Figure 6A-C) , we did observe a dramatic decrease in phospho-Smad2 staining in pulmonary metastases from 4T1-TbRIII tumors relative to pulmonary metastases from 4T1-TbRIII-cyto and 4T1-Neo tumors ( Figure 6D-G) . These results suggest that TbRIII specifically suppresses TGF-b signaling in the metastatic tumor microenvironment specifically through functions mediated through its cytoplasmic domain.
Discussion
Breast cancer remains a leading cause of morbidity and mortality worldwide, with most of this morbidity and mortality resulting from recurrent and metastatic disease (27) . Previous studies have amply demonstrated an important role for TGF-b signaling during mammary carcinogenesis. In early breast cancer progression, TGF-b generally acts as a tumor suppressor, inhibiting proliferation and promoting apoptosis. However, breast cancer cells in an established tumor become resistant to TGF-b-mediated effects on proliferation and apoptosis through an incompletely understood process and instead respond with increased migration and invasion. We have previously reported that the TGF-b superfamily co-receptor TbRIII is a suppressor of breast cancer progression, with frequent loss during breast cancer progression corresponding with decreased patient survival (11) . Functionally, TbRIII inhibited tumor invasiveness in vitro and tumor invasion, angiogenesis and metastasis in vivo (11). Mechanistically, TbRIII appeared to function, at least in part, by undergoing ectodomain shedding, with the resulting sTbRIII antagonizing TGF-b signaling to reduce invasiveness and angiogenesis in vivo (11) . In the present study, we further investigate the mechanism by which TbRIII mediates its suppressor of cancer progression function. We demonstrate that the cytoplasmic domain of TbRIII has an important role in TbRIII-mediated suppression of cancer progression, as deletion of the cytoplasmic domain abolishes the ability of TbRIII to inhibit migration or invasion in vitro and invasion and cancer progression in vivo.
Mechanistically, TbRIII-mediated inhibition of migration and invasion appears to be modulated by TbRIII-mediated inhibition of TGF-b signaling, as supported by (i) the tight correlation between the ability of TbRIII mutants to inhibit TGF-b signaling and to inhibit migration and invasion in vitro; (ii) the tight correlation between diminished TGF-b signaling and decreased invasion and metastasis mediated by TbRIII in vivo; (iii) the ability of directly inhibiting TGF-b signaling to mimic the effects of TbRIII on inhibiting migration in vitro and (iv) the ability of bypassing TbRIII-mediated inhibition of TGF-b signaling to abrogate TbRIII-mediated inhibition of migration and invasion in vitro. Finally, we demonstrate that a discrete function of the cytoplasmic domain of TbRIII, namely binding to the PDZ domain-containing protein, GIPC, is largely responsible for mediating the effects of TbRIII on inhibiting TGF-b signaling and inhibiting cell migration and invasion in vitro, as either inhibiting the ability of TbRIII to bind GIPC or silencing GIPC expression is sufficient to abolish these effects. These results provide another mechanism by which TbRIII mediates its suppressor of cancer progression effects and emphasize the importance of the conserved TbRIII cytoplasmic domain in mediating TbRIII functions. How does TbRIII inhibit TGF-b signaling through its cytoplasmic domain and GIPC-binding function? While we have previously demonstrated that TbRIII can inhibit TGF-b signaling through generation of sTbRIII, which sequesters TGF-b to inhibit TGF-b signaling (11), here we demonstrate that TbRIII and TbRIII-cyto do not differ in their ability to produce or to inhibit cell migration through sTbRIII. Thus, differences in generation of sTbRIII probably do not account for cytoplasmic domain-mediated inhibition of TGF-b signaling. We have also previously demonstrated that GIPC binding to TbRIII stabilized TbRIII on the cell surface and increased TGF-b signaling in epithelial cells and myoblasts (18) . However, these studies utilized GIPC overexpression as opposed to the loss of function studies performed here. In addition, breast epithelial and/or breast cancer cells could have altered responsiveness to GIPC relative to the mink lung epithelial and rat myoblasts used in our prior studies (18) . Indeed, TbRIII has already been demonstrated to have context-dependent effects on TGF-b signaling, also inhibiting TGF-b signaling in LLC-PK1 porcine epithelial cells (28) . Furthermore, in the prior (D and F) ; note that the TbRIII-cyto tumor impinges upon the airway (F), whereas the tumor adjacent to the airway in the TbRIII tumor retains its architecture (E). Liver metastases were also noted in the Neo and TbRIII-cyto groups (G and I), whereas none of the TbRIII liver tissues examined revealed metastatic lesions (H). A metastatic tumor in the kidney was noted in one of the TbRIII-cyto mice (J); Scale bar 5 100 lm.
Type III TGF-b receptor cytoplasmic domain in breast cancer studies, we focused on TGF-b-mediated inhibition of proliferation and TGF-b-stimulated gene expression, without examining direct effects on Smad phosphorylation (18) , whereas here, we focused on TGF-b-mediated Smad phosphorylation and effects on migration and invasion. In any case, the ability of GIPC to regulate to cell surface stability of TbRIII suggests that GIPC might serve to regulate TGF-b signaling by regulating its internalization and trafficking. Consistent with this hypothesis, the other scaffolding protein that interacts with the cytoplasmic domain of TbRIII, b-arrestin2, functions to regulate TbRIII endocytosis and TGF-b signaling (17) . In addition, we have demonstrated that internalization of TbRIII through both clathrin-dependent and clathrin-independent signaling pathways is important for TbRIII-mediated signaling through both Smad-dependent and Smad-independent signaling pathways (23) . Alternatively, GIPC could be functioning as a scaffolding protein to link TbRIII to other pathways that either directly or indirectly inhibits TGF-b signaling. As we have demonstrated that the interaction of GIPC with TbRIII can have context-dependent effects on TGF-b signaling, current studies are aimed at defining the precise mechanism by which TbRIII and GIPC function to regulate TGF-b signaling, including the connection between receptor trafficking and signaling.
Here, we present data supporting a model for TbRIII in inhibiting breast cancer progression through inhibition of TGF-b signaling, not through generation of sTbRIII but through its cytoplasmic domain. In separate studies, we have also demonstrated that TbRIII might inhibit breast cancer progression through TGF-b signaling-independent and b-arrestin2-dependent activation of Cdc42 to inhibit breast cancer cell migration (16) as well as through b-arrestin2-dependent inhibition of nuclear factor-kappaB signaling to inhibit breast cancer cell migration (24) . Taken together, these results suggest several mechanisms that could either act in concert or in isolation to mediate the suppressor of cancer progression function of TbRIII. These multiple mechanisms by which TbRIII functions also provide an explanation for the selective pressure which probably results in the frequent loss of TbRIII expression during breast cancer progression, as we have already reported (11) . While these mechanisms may function in isolation, as TbRIII-cyto also produces sTbRIII (supplementary Figure 1A is available at Carcinogenesis Online), why does it not have any effect in inhibiting cell migration and invasion in vitro and cancer progression in vivo? While this paradox remains to be fully explored, it is possible that the different mechanisms defined operate in different contexts or that TbRIII-cyto, which cannot be internalized and downregulated (23) , functions as a constitutively active ligand presenter and functionally competes with sTbRIII as a suppressor of signaling. These possibilities are currently being explored with extracellular domain mutants to further delineate the contribution of the cytoplasmic domain in TGF-b signaling and migration and invasion.
In summary, our work has demonstrated that the cytoplasmic domain of TbRIII is critical for its function in inhibiting migration and invasion, as well as TbRIII's role in attenuating TGF-b signaling. In vivo, the cytoplasmic domain is important for the ability of TbRIII to inhibit metastatic potential. Furthermore, we have identified the interaction with GIPC as a critical mediator of TbRIII's effects 
